Spyre Therapeutics (SYRE) Current Deferred Revenue (2016 - 2023)

Spyre Therapeutics (SYRE) has 5 years of Current Deferred Revenue data on file, last reported at $930000.0 in Q2 2023.

• Quarterly Current Deferred Revenue fell 65.56% year-over-year to $930000.0 in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $930000.0 (down 65.56% YoY) and the FY2022 annual result came in at $517000.0, down 78.08% from the prior year.
• Current Deferred Revenue advanced to $930000.0 in Q2 2023, from $302000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $19.2 million in Q1 2021 to a low of $302000.0 in Q1 2023.
• A 3-year average of $3.9 million and a median of $2.2 million in 2021 frame the typical range for Current Deferred Revenue.
• The widest YoY moves for Current Deferred Revenue: up 50.91% in 2022, down 89.48% in 2022.
• Tracing SYRE's Current Deferred Revenue over 3 years: stood at $2.4 million in 2021, then slumped by 78.08% to $517000.0 in 2022, then surged by 79.88% to $930000.0 in 2023.
• The last three Current Deferred Revenue figures came in at $930000.0 (Q2 2023), $302000.0 (Q1 2023), and $517000.0 (Q4 2022), per Business Quant data.